Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Bioinformatics analysis
Differentially expressed genes
Prostate cancer
Protein–protein interaction network
miRNAs
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
09
05
2018
accepted:
15
10
2018
pubmed:
28
10
2018
medline:
3
4
2020
entrez:
28
10
2018
Statut:
ppublish
Résumé
The increasing number of datasets available in the GEO database offers a new approach to identify new miRNAs related to PCa. The aim of our study was to suggest a miRNA signature for the detection of high-grade PCa (Gleason score ≥ 7) using bioinformatics tools. Three mRNA datasets (GSE26022, GSE30521, GSE46602) were selected to identify the differentially expressed genes (DEGs) in high-grade PCa. Furthermore, two miRNA datasets (GSE45604, GSE46738) were analyzed to select the differentially expressed miRNAs (DEMs). Functional and pathway enrichment analysis was performed using DAVID and a protein-protein interaction network (PPI) was constructed through STRING. Besides, miRNAs which regulate hub genes were predicted using microRNA.org . A total of 973 DEGs were identified after the analyses of the mRNA datasets, enriched in key mechanisms underlying PCa development. Furthermore, we identified 10 hub genes (EGFR, VEGFA, IGF1, PIK3R1, CD44, ITGB4, ANXA1, BCL2, LPAR3, LPAR1). The most significant KEGG Pathway was PI3K-Akt signaling pathway, involved in cell proliferation and survival. Moreover, we identified 30 common miRNAs between significant DEMs and the predicted hub gene regulators. Twelve of these miRNAs (miR-1, -365, -132, -195, -133a, -133b, -200c, -339, -222, -21, -221, -708) regulate two or more hub genes identified in our study. We suggested a signature including these 12 miRNAs for high-grade PCa detection. These miRNAs have been associated with aggressive PCa, poor survival and resistance to treatment in the last years.
Identifiants
pubmed: 30367364
doi: 10.1007/s12253-018-0508-3
pii: 10.1007/s12253-018-0508-3
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1445-1456Références
Cancer Res. 2015 Aug 1;75(15):3077-86
pubmed: 26071255
Cancer Res. 2008 Aug 1;68(15):6162-70
pubmed: 18676839
J Biol Chem. 2010 May 14;285(20):14980-9
pubmed: 20231295
PLoS One. 2012;7(10):e47067
pubmed: 23115635
Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52
pubmed: 12539951
Mol Cancer. 2010 Jan 21;9:12
pubmed: 20092645
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Urol. 2014 Dec;21(12):1209-14
pubmed: 25099119
Sci Rep. 2015 Nov 02;5:16018
pubmed: 26522007
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Br J Cancer. 2012 Jan 17;106(2):405-13
pubmed: 22068816
Prostate. 2018 May;78(6):411-418
pubmed: 29383739
Oncol Rep. 2016 Jul;36(1):376-82
pubmed: 27175617
Oncogene. 2000 Dec 27;19(56):6550-65
pubmed: 11426640
Br J Cancer. 2015 Sep 29;113(7):1055-65
pubmed: 26325107
Int J Oncol. 2014 May;44(5):1571-80
pubmed: 24603851
Onco Targets Ther. 2017 Oct 24;10:5089-5097
pubmed: 29123407
Oncogene. 2014 May 22;33(21):2790-800
pubmed: 23770851
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Am J Pathol. 2012 Nov;181(5):1585-94
pubmed: 23083832
Clin Cancer Res. 2002 Nov;8(11):3438-44
pubmed: 12429632
PLoS One. 2014 Oct 31;9(10):e108780
pubmed: 25360799
Am J Clin Oncol. 2010 Dec;33(6):609-13
pubmed: 20042973
J Biol Chem. 2009 Feb 27;284(9):5731-41
pubmed: 19073608
Clin Chem. 2016 Oct;62(10):1318-33
pubmed: 27540032
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Cancer Res. 2008 Oct 15;68(20):8195-200
pubmed: 18922890
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
pubmed: 19302977
Oncotarget. 2015 Sep 15;6(27):24017-31
pubmed: 26172296
Cancer Res. 2008 Apr 15;68(8):2773-80
pubmed: 18413744
Epigenetics. 2010 Feb 16;5(2):100-4
pubmed: 20160483
Am J Clin Exp Urol. 2014 Oct 02;2(3):231-8
pubmed: 25374925
PLoS One. 2008;3(12):e4029
pubmed: 19107213
J Clin Oncol. 2005 Nov 10;23(32):8253-61
pubmed: 16278481
Cancer Genet. 2015 Jun;208(6):289-302
pubmed: 26004033
J Urol. 2014 Jul;192(1):252-9
pubmed: 24518785
Oncology (Williston Park). 2014 Jan;28(1):16-22
pubmed: 24683714
Clin Chem Lab Med. 2017 May 1;55(5):715-736
pubmed: 26751899
Cancer Lett. 2017 Aug 1;400:9-17
pubmed: 28450158
Cancer Res Treat. 2012 Mar;44(1):50-6
pubmed: 22500161
FEBS Open Bio. 2016 Jun 08;6(7):735-41
pubmed: 27398313
J Cell Biochem. 2017 Dec;118(12):4331-4340
pubmed: 28430389
Genome Biol. 2010;11(8):R90
pubmed: 20799968
PLoS One. 2014 Jun 03;9(6):e98833
pubmed: 24892674
Exp Cell Res. 2003 Mar 10;284(1):31-53
pubmed: 12648464
Oncogene. 2013 Apr 4;32(14):1843-53
pubmed: 22614007